Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 4 Thyroid Carcinoma, Anaplastic 3 Neoplasms 3 Glioma 3 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Recurrence 1 Rare Malignant Neoplasm 1 Oligodendroglioma 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neurocytoma 1 Neuroblastoma 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Locally Advanced Thyroid Gland Carcinoma 1 Histiocytosis, Langerhans-Cell 1 Hematologic Neoplasms 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Eunuchism 1

Interventions

trametinib 1 dabrafenib 1 Surgical Procedures, Operative 1 Pharmaceutical Preparations 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Malignant Neoplasm × dabrafenib × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡